Abstract
Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is an extensively studied ligand-activated nuclear hormone receptor that functions as transcription factor and plays an important role in diverse biological processes, such as lipid metabolism and insulin sensitization. Recent studies have demonstrated that PPARγ is over-expressed in many tumor types, including breast cancer, suggesting a possible role in tumor development and/or progression and a putative prognostic value. Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition, apoptosis and differentiation of tumor cells. The present review summarizes the available information on PPARγ expression in breast tumors and the use of PPARγ ligands as anti-cancer agents for breast cancer treatment, both in vitro and in vivo. Considering the data so far, specific PPARγ agonists seem to exert beneficial effects against breast cancer and may therefore represent potential therapeutic agents.
Keywords: 15-deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2), Anti-cancer agents, Apoptosis, Breast cancer, Cell cycle arrest, Differentiation, Estrogen Receptors (ERs), Fatty acids, Growth inhibition, Ligands, Methylene-substituted diindolylmetyhanes (CDIMs), Oncogenesis, Peroxisome Proliferator-Activated Receptor-γ (PPARγ), Prognostic value, Retinoid-X-Receptor (RXR), Statins, Thiazolidinediones (TZDs)
Anti-Cancer Agents in Medicinal Chemistry
Title:The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer
Volume: 12 Issue: 9
Author(s): Ioly Kotta-Loizou, Constantinos Giaginis and Stamatios Theocharis
Affiliation:
Keywords: 15-deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2), Anti-cancer agents, Apoptosis, Breast cancer, Cell cycle arrest, Differentiation, Estrogen Receptors (ERs), Fatty acids, Growth inhibition, Ligands, Methylene-substituted diindolylmetyhanes (CDIMs), Oncogenesis, Peroxisome Proliferator-Activated Receptor-γ (PPARγ), Prognostic value, Retinoid-X-Receptor (RXR), Statins, Thiazolidinediones (TZDs)
Abstract: Peroxisome Proliferator-Activated Receptor-γ (PPARγ) is an extensively studied ligand-activated nuclear hormone receptor that functions as transcription factor and plays an important role in diverse biological processes, such as lipid metabolism and insulin sensitization. Recent studies have demonstrated that PPARγ is over-expressed in many tumor types, including breast cancer, suggesting a possible role in tumor development and/or progression and a putative prognostic value. Moreover, naturally-occurring and synthetic PPARγ agonists promote growth inhibition, apoptosis and differentiation of tumor cells. The present review summarizes the available information on PPARγ expression in breast tumors and the use of PPARγ ligands as anti-cancer agents for breast cancer treatment, both in vitro and in vivo. Considering the data so far, specific PPARγ agonists seem to exert beneficial effects against breast cancer and may therefore represent potential therapeutic agents.
Export Options
About this article
Cite this article as:
Kotta-Loizou Ioly, Giaginis Constantinos and Theocharis Stamatios, The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (9) . https://dx.doi.org/10.2174/187152012803529664
DOI https://dx.doi.org/10.2174/187152012803529664 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Mesenchymal Stem Cells and Their Cell Surface Receptors
Current Rheumatology Reviews Smart Synthetic Polymer Nanocarriers for Controlled and Site-Specific Drug Delivery
Current Topics in Medicinal Chemistry Elaborating the Role of Natural Products on the Regulation of Autophagy and their Potentials in Breast Cancer Therapy
Current Cancer Drug Targets Design and Application of Magnetic-Based Theranostic Nanoparticle Systems
Recent Patents on Biomedical Engineering (Discontinued) Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry Synthesis and Cytotoxicity Studies of New Morpholino-Functionalised and N-Heteroaryl-Substituted Titanocene Anticancer Drugs
Medicinal Chemistry Triazole-linked Chalcone and Flavone Hybrid Compounds Based on AZT Exhibiting In Vitro Anti-Cancer Activity
Letters in Drug Design & Discovery Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Multiscale Imaging of Nanoparticle Drug Delivery
Current Drug Targets Combined Cancer Therapy: Strategies to Overcome Acquired Aromatase Inhibitor Resistance
Current Pharmaceutical Design Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies The ACE Insertion/Deletion Polymorphism and Risk of Cancer, a Review and Meta-Analysis of the Literature
Current Cancer Drug Targets Shaping Tumor Microenvironment for Improving Nanoparticle Delivery
Current Drug Metabolism NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews